Oppenheimer Begins Covering VolitionRX (AMEX:VNRX) Stock. “Shares to Hit $7.0000”

May 23, 2018 - By Marie Mckinney

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Investors sentiment decreased to 1.2 in Q4 2017. Its down 5.80, from 7 in 2017Q3. It dived, as 3 investors sold VolitionRx Limited shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 4.52 million shares or 51.36% less from 9.30 million shares in 2017Q3 were reported.

Blackrock has 0% invested in VolitionRx Limited (NYSEAMERICAN:VNRX). Lagoda Inv Mngmt Limited Partnership reported 3.52 million shares or 3.94% of all its holdings. Royal National Bank Of Canada has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Vanguard Group invested in 0% or 204,994 shares. Geode Cap Mngmt Limited Liability Co has 100,890 shares for 0% of their portfolio. Garrison Bradford & Associate stated it has 15,500 shares. Brown Brothers Harriman & Communications holds 3,823 shares or 0% of its portfolio. Bessemer Grp Incorporated stated it has 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Knoll Cap Limited Partnership accumulated 351,538 shares or 0.91% of the stock. Creative Planning invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Morgan Stanley invested in 0% or 63,400 shares. Northern holds 22,714 shares or 0% of its portfolio. Financial Bank Of New York Mellon Corporation holds 10,335 shares or 0% of its portfolio. Bridgeway Capital Mngmt has invested 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Leisure Cap Management reported 0.18% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX).

Why Has Oppenheimer Given VolitionRX (AMEX:VNRX) a $7.0000 Price Target

Oppenheimer analyst began coverage on VolitionRX (AMEX:VNRX) with a $7.0000 target price and Buy rating. The target price would indicate a potential upside of 192.89 % from company’s current price.

VolitionRx Limited (NYSEAMERICAN:VNRX) Ratings Coverage

Among 2 analysts covering VolitionRX (AMEX:VNRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VolitionRX has $10.0 highest and $6 lowest target. $8’s average target is 234.73% above currents $2.39 stock price. VolitionRX had 4 analyst reports since January 29, 2018 according to SRatingsIntel. As per Monday, March 5, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained VolitionRx Limited (NYSEAMERICAN:VNRX) rating on Tuesday, February 6. H.C. Wainwright has “Buy” rating and $10.0 target. H.C. Wainwright maintained it with “Buy” rating and $10.0 target in Monday, January 29 report.

The stock increased 6.70% or $0.15 during the last trading session, reaching $2.39. About 254,643 shares traded or 84.00% up from the average. VolitionRx Limited (AMEX:VNRX) has declined 42.82% since May 23, 2017 and is downtrending. It has underperformed by 54.37% the S&P500.

Analysts await VolitionRx Limited (NYSEAMERICAN:VNRX) to report earnings on August, 8. They expect $-0.17 EPS, down 30.77 % or $0.04 from last year’s $-0.13 per share. After $-0.17 actual EPS reported by VolitionRx Limited for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $71.77 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: